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Abstract
Glial tumors have demonstrated abilities to sustain growth via recruitment of glial progenitor cells
(GPCs), which is believed to be driven by chemotactic cues. Previous studies have illustrated that
mouse GPCs of different genetic backgrounds are able to replicate the dispersion pattern seen in
the human disease. How GPCs with genetic backgrounds transformed by tumor paracrine
signaling respond to extracellular cues via migration is largely unexplored, and remains a limiting
factor in utilizing GPCs as therapeutic targets. In this study, we utilized a microfluidic device to
examine the chemotaxis of three genetically-altered mouse GPC populations towards tumor
conditioned media, as well as towards three growth factors known to initiate the chemotaxis of
cells excised from glial tumors: Hepatocyte Growth Factor (HGF), Platelet-Derived Growth
Factor-BB (PDGF-BB), and Transforming Growth Factor-α (TGF-α). Our results illustrate that
GPC types studied exhibited chemoattraction and chemorepulsion by different concentrations of
the same ligand, as well as enhanced migration in the presence of ultra-low ligand concentrations
within environments of high concentration gradient. These findings contribute towards our
understanding of the causative and supportive roles that GPCs play in tumor growth and
reoccurrence, and also point to GPCs as potential therapeutic targets for glioma treatment.
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INTRODUCTION
Gliomas are the most common form of primary brain cancer present in adults, affecting 10%
of the worldwide cancer population and harboring a 5-year survival rate of less than
25%.8,67,76 These glial tumors pose unique clinical challenges because their aggressive
migration within healthy brain tissue minimizes the effectiveness of surgical resection.1,51,68
A wealth of evidence now demonstrates that bulk tumor growth can occur via extensive cell
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proliferation,12,53,62 as well as by aggressive recruitment of surrounding cells.3,9,21,72 Glial
tumors have demonstrated the ability to recruit a variety of cells via paracrine signaling to
maintain and extend tumor survival,22 including stem cells,28,49 endothelial cells,25
macrophages79 and endogenous precursors,3,29 or glial progenitor cells (GPCs).
A recent in vivo study demonstrated that GPCs were able to migrate from the brain
subventricular zone (SVZ) towards pre-existing glial tumors and then surround the tumor
mass.17,22 Such GPC recruitment by glial tumors is believed to be driven by chemotactic
cues, i.e. chemical concentration gradients that stimulate cell migration towards a tumor
mass.67,88 Studies using mouse glial progenitors have demonstrated that different
populations of GPCs exhibit distinct patterns of migration that are replicated in the human
disease. 6,64 For example, populations of GPCs have been seen to invade the brain as
individual cells, as well as via chain cell migration along the vasculature.58,65 Interestingly,
such differences in migratory phenotype have been seen across cells where the intracellular
signaling was accomplished via the same pathway.58,65 Whether distinct GPC migratory
phenotypes become acquired with genetic backgrounds altered via tumor paracrine signaling
is unknown. Further, how genetically transformed cells respond to extracellular cues via
migration is largely unexplored, and remains a limiting factor in utilizing GPCs as
therapeutic targets.
In this study we examine the in vitro migration of varying populations of genetically-altered
GPCs in order to examine how defined microenvironments affect the chemotaxis of the
different GPC populations. We examine the growth factor-induced migration of cells
derived from three primary mouse GPC types and one primary mouse tumor alongside two
well-studied human glioblastoma cell lines. Here, we examine the chemoattractant strength
of three principle growth factors Hepatocyte Growth Factor (HGF), Platelet-Derived Growth
Factor Beta (PDGF-B), and Transforming Growth Factor Alpha (TGF-α) because of the
extensive evidence that documents their induced migration of cells derived from glial
tumors.7,18,19,40,55,59 Our results illustrate that despite the different migratory mechanisms
employed by the GPC types, all GPCs exhibited chemoattraction and chemorepulsion by
different concentrations of the same ligand, as well as enhanced migration in the presence of
ultra-low ligand concentrations within environments of high concentration gradient. In
addition, all GPCs studied were observed to migrate much shorter distances than their
glioblastoma-derived counterparts, suggesting that glial tumors may recruit and/or transform
highly localized GPCs to enhance growth. Our study provides data to merit examination of
GPCs as potential drug delivery vehicles to the bulk tumor mass, and adds to the growing
body of literature that points towards the study of GPC migration as a means to reduce
tumor recurrence and/or growth. Lastly, our study is the first to document glial
chemoresponsiveness within low concentration environments, which has been previously
unexplored in the literature and can significantly impact the testing of therapeutic agents
tailored to glioma therapy.
MATERIALS AND METHODS
Cell Culture
Three glial progenitor mouse cell types, one primary mouse tumor and two human tumor
cell lines were used in this study. The GPCs of varying genetic backgrounds were chosen
because they each represent a cell population that is associated with specific types of tumors
present within human brain. GPCs were derived from the RCAS/Ntv-a system from the
laboratory of Dr. Eric C. Holland laboratory at Memorial Sloan Kettering Cancer Center,
New York.26,31,52 The Ntv-a transgenic mouse line is comprised of retroviral vectors and
mice transgenic for cell type specific expression of the retroviral receptor, tv-a. Briefly, the
Ntv-a transgenic mouse line was constructed by expressing tv-a as a transgene from the
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nestin promoter. The RCAS viral vectors are avian-specific and only infect mammalian cells
engineered to express the tv-a receptor. The Ntv-a system accomplishes glial-specific gene
transfer, which permits study of the role of single and multiple mutations in transformed
cells of glial lineage.
The four mouse cell types derived from the Ntv-a system used in this study were: (a)
GPCLacZ cells: GPCs infected with the RCAS vector to express β-galactosidase41 and used
as our control cell type. These cells do not harbor genetic abnormalities specifically
associated with glial tumors, but rather represent a progenitor cell type found in different
regions of the brain that can be recruited to aid in tumor growth12 (b) GPCPDGF cells: GPCs
infected with the RCAS vector to develop an autocrine Platelet-Derived Growth Factor
(PDGF)-Platelet-Derived Growth Factor Receptor (PDGFR) loop.12 These cells have been
engineered to mimic the characteristics of cells present in astrocytomas, where a PDGF
autocrine loop is believed to be responsible for increased proliferation as well as enhanced
group migration in the brain12,45 (c) GPCkRas cells: GPCs infected with RCAS vector that
generates constitutively-activated downstream Ras pathways.32 These cells are characteristic
of oligodendrocytomas that present with large diffuse spreading of cells which maintain
contact with one another in the brain33,63 and (d) XFMPDGF cells: Derived from a mouse
oligodendrocytoma engineered to express secreted PDGF-B in mice with a INK4a-Arf−/−
background.26,69 The XFMPDGF and GPCPDGF cells are similar in their ability to produce
and respond to their own PDGF, but XFMPDGF cells have the INK4a-Arf locus deleted,
disabling possible tumor suppressor capabilities. Note that GPCLacZ, GPCPDGF and
GPCkRas cells were generated via RCAS infection in culture dishes, while XFMPDGF cells
were harvested from an excised, induced mouse tumor as shown in Fig. 1. In addition, the
two human glioblastoma cell lines studied were U-87 MG (ATCC Cat # HTB-14™) and
U-251 MG (ATCC Cat # HTB-17™). These cell lines were examined alongside GPCs
because they have been extensively used in glioma research, both in vivo and in vitro.
All cells were cultured using sterile Dulbecco’s Modified Eagle Medium (DMEM) (Cat#:
10-017-CV, Mediatech, VA), supplemented with 2% L-Glutamine (Cat#: 25-015-CI,
Mediatech, VA), 2% Penicillin-Streptomycin–Amphotericin B—100× solution (Cat#:
30-002-CI, Mediatech, VA), and 10% fetal bovine serum (FBS) (Cat#: MT35-010-CV,
Mediatech, VA). The cells were grown onto sterile polystyrene tissue culture flasks (BD
Biosciences, Franklin Lakes, NJ) and incubated at 37 °C with 5% CO2.
Growth Factors
Three growth factors were used to examine chemotaxis in this study: Hepatocyte Growth
Factor/Scatter Factor (HGF) (Molecular Weight = 80 kDa) (Cat#: 2207-HG/SF, R&D
Systems, MN), Platelet Derived Growth Factor-BB (PDGF) (Molecular Weight = 12.4 kDa)
(Cat#: 220-BB, R&D Systems, MN), and Transforming Growth Factor α (TGF-α)
(Molecular Weight = 6 kDa) (Cat#: 616430, Calbiochem & Oncogene, CA). Growth factors
were diluted with serum-free DMEM to obtain a concentration range for each experiment
between 1 pM and 10 nM.
Chemotaxis Assays
Cellular chemotaxis in response to extracellular signaling from growth factors was analyzed
via transwell assays, as described previously.7,50 Briefly, a modified thick coating volume of
200 μL of 0.5 mg/mL Matrigel™ (Cat#: 356230, BD Bioscience, MA) was used to coat the
polyethylene terephthalate (PET) membranes with 8 μm-diameter pores, which separated the
upper and lower chambers of the transwell system. The matrix was polymerized after a 3-h
incubation period at 37 °C, and the uncovered culture plates were placed into a class II
biological flow hood for 48 h to dry. Upon drying, plates were wrapped in aluminum foil
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and stored at 4 °C for future experiments. Coated filters were rehydrated with 200 μL serum
free DMEM and incubated at 37 °C for 1-h immediately prior to their use.
Growth factor solutions between 1 pM and 10 nM concentrations were added to the lower
chamber of a 24-well plate (Cat#: BD353047, BD Bioscience, MA), while cell solutions at a
density of 1.5 × 106 cells per mL of supplemented DMEM were added to the upper chamber
culture inserts (Cat#: BD353097, BD Bioscience, MA). The transwell assay was incubated
for 12 h at 37 °C to allow cells migrate through the porous membrane, after which excess
cell solution was aspirated from culture inserts. Cells on the upper side of the membrane
were removed, and cells on the lower side of the membrane were fixed and stained with
Diff-Quick® Stain Set (Dade Behring, DE) to facilitate cell counting. The nuclei of cells that
migrated to the underside of the membrane were counted using an inverted light microscope
with a 20× objective (Nikon TE300, Morrell Instruments, NY). Cells located within five
areas of the culture inserts were counted upon each filter using a checkerboard pattern87 for
a total of five rectangular locations of 0.58 mm × 0.44 mm. These data were used to gather
representative cell counts per experiment (n > 7).
Conditioned Media Chemotaxis Assays
Cells derived from U-87, U-251, and XFMPDGF tumors were grown separately in T-75
tissue culture flasks in supplemented DMEM. Once 90–95% confluence was reached,
complete media was replaced with 10 mL of serum-free DMEM and cells were incubated
for 24–48 h. Supernatant was collected and serially diluted in serum-free DMEM to
concentration ratios of 1:0 (100% or non-diluted), 1:1 (50%), and 1:4 (25%). Conditioned
media (CM) was used in lieu of growth factor solutions within transwell assays for these sets
of experiments (n ≥ 3). Conditioned media of tumor cell samples (U-87, U-251, and
XFMPDGF) was collected by serum starving respective cells for 24–48 h prior to testing. In
this way, we better examined the migration of GPCs to growth factors generated by the
tumor cell samples themselves, without the influence of serum, as done previously in the
literature.5,23,66,71
Relative Chemoattractant Factor (RCF)
Cell migration indexes are reported here using a parameter called the Relative
Chemoattractant Factor (RCF). RCF is defined as the normalized cell count per experiment,
and is determined by dividing the average number of cells that migrated towards the test
solutions, NTest, by the average number of cells that migrated towards the control solution
(in this case serum-free DMEM), NControl. In this way, RCF represents the fold increase in
cell migration from control experiments to experimental conditions, as described by Eq. (1).
(1)
Statistical Analysis
RCF values calculated during migration assays were analyzed by analysis of variance
(ANOVA) to determine the statistical differences between experimental groups and
Student’s t test to determine the statistical differences between individual experimental
groups and controls. p values less than 0.05 were defined as statistically significant (*).
Antibodies and Immunocytochemistry
Sequential, double immunofluorescence for detection of growth factor receptors was
performed as described previously.14 Briefly, cells grown on coverslips were fixed for 15
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min at room temperature with paraformaldehyde (Cat#: P6148, Sigma, St. Louis, MO) and
labeled with rabbit polyclonal anti-β-actin (1:1000) (Cat#: ab8227, Abcam, Cambridge,
MA), rabbit monoclonal anti-phosphorylated-EGF-R (1:500) (Cat#: ab40815, Abcam,
Cambridge, MA), anti-rabbit AlexaFluor® 488 or 594 antibodies (Cat#: A11034 and
A11037, respectively, Invitrogen, Camarillo, CA).
Immunoblotting and Detection
Protein lysates were generated from 90 to 95% confluent serum starved cells grown in 100-
mm culture plates and done in triplicate (Becton-Dickinson, MA). All cells were serum
starved for 2 h in 1× PBS at 37 °C and separately stimulated for 20 min using the specified
growth factor concentrations that correlated with maximum RCF values determined from
transwell assays. Cells were lysed at 4 °C on ice in cold lysis buffer (Cat#: 2978-50, Sigma,
MO) containing 70 μL Protease Inhibitor (Cat#: 78425, Pierce IL), 2 mM
phenylmethylsulfonyl fluoride (Cat#: P7626, Sigma-Aldrich MO) and 10 μL Phosphatase
Inhibitor Cocktail 2 (Cat#: P5726, Sigma-Aldrich MO) for 15 min. Proteins, 40 μg/well,
were separated by 8–16% Tris-Glycine SDS-PAGE precast gels (CAT#58519, Lonza,
Rockland, ME), then transferred to nitrocellulose membranes. The stimulation of EGFR
tyrosine phosphorylation in GPCLacZ by 1 pM TGF-α, in GPCPDGF by 100 pM TGF-α, and
in GPCkRas by 1 pM TGF-α (Fig. 6) was accomplished via a 20 min incubation period in the
presence of the designated growth factor concentration.
Detection of protein expression was performed using corresponding primary antibodies, the
IRDye® 800 CW goat polyclonal anti-rabbit secondary (Cat#: 926-32211, LiCor
Biosciences, Lincoln, NE) and the Odyssey Infrared Scanner at 795 nm (LiCor Biosciences,
Lincoln, NE). An average intensity measurement, I, was made by selecting a rectangular
region (created via the Odyssey software’s select tool) that encompassed the entire band area
of a membrane to record its intensity during imaging. The identical rectangular region was
then overlaid onto remaining band areas to determine the average intensity for each band.
The average intensity of each experimental condition (e.g. growth factor-stimulated or not)
was then divided by the average intensity of the control condition. In this manner, the
intensity of control bands have been normalized to I = 1, such that reported values of
average intensity for experimental conditions reflect a fold-increase or fold-decrease
compared to controls.
Confocal Microscopy
Confocal laser scanning microscopy imaging was performed using a Leica TCS SP2
instrument with a HCX PL APO CS 63× oil immersion objective (NA 1.4). Imaging
conditions used for each set of experiments were set with Ar/HeNe Laser at 20%; a 1024 ×
1024 format; gain range of 600–700 V; 0.5% offset; and a 200-Hz scanning speed.
μLane System
The laboratory-developed μLane system used for this study has been previously
described.38,39 In brief, systems are comprised of a 5-cm-long glass microscope slide
bonded to a polydimethylsiloxane (PDMS) elastomer. As shown in Figs. 2a and 2b, the
design includes a sink reservoir (V = 200 μL), and a source reservoir (V = 10 μL). The
reservoirs are connected by a single microchannel of 100 μm by 100 μm crosssection and
1.5 cm length. The system works via diffusion, whereby growth factors present in high
concentration in the source reservoir and channel diffuse towards lower concentration within
the sink reservoir to create concentration gradients that stimulate cell migration. In these
tests, the microchannel was first filled with a solution of 2 μg/mL of growth factor reduced
Matrigel™ (BD Bioscience, MA, Cat: 354230) containing a desired growth factor
concentration and incubated at 37 °C for 1.5 h to enable Matrigel™ polymerization. All
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experiments were performed using growth factor reduced Matrigel™ as the control ECM.
Then, excess matrix was aspirated from the sink reservoir and replaced with cell solution at
a density of 1.5 × 106 cells/mL. The system was then incubated at 37 °C. Cell movement
into the microchannel from the sink reservoir was monitored via light microscopy using a
20× long working distance dry objective and a cooled CCD camera. Images of cells moving
from the sink reservoir into the microchannel were recorded at t = 12 h, t = 24 h, and t = 36
h using Nikon software (Nikon Instrument Element 2.30 with 6D module, Morrell
Instrument Company Inc., Melville, NY). The numbers of cells that migrated into the
microchannels were counted within three regions within the channel, 0–200 μm, 200–400
μm, and 400–600 μm. Experiments were completed in triplicate using newly fabricated
μLane systems for each experiment.
Mathematical Modeling
Diffusion within the μLane system was modeled using Fick’s Law described by Eq. (2).
(2)
where C is concentration (ng/mL), t (s) is time, D (m2/s) is the diffusion coefficient, and x
(m) is distance. 1-D modeling was appropriate for this system because the channel length, L,
was substantially larger than its diameter, D, with L/D>100. Equation (2) was solved using
Finite-element-analysis software Matlab 7.7 (Math Works, Natick, MA), with an initial
concentration, C0, set throughout the channel length that was either 10 pM or 100 pM, as per
experiment. The boundary conditions were fixed at C = 0 at x = 0, i.e. entrance of the
channel from the sink reservoir, and C = C0 at x = L, i.e. the entrance of the channel at the
source reservoir end, for all time, t. Analysis via Fick’s law enabled computation of
concentration profiles within the μLane for all times. The simulation revealed that the
concentration distribution within the microchannel reached steady-state at t = 103 h, after
which no changes in concentration with time were seen. Concentration gradients were
obtained by calculating the change in concentration along the channel length as done
previously15 via Eq. (3):
(3)
where G is gradient, C is concentration (ng/mL), and x (m) is distance.
RESULTS
Glial Progenitor Cells Exhibit a Dose-Dependent Response to Tumor-Conditioned Media
(CM)
In order to examine the migratory behavior of GPCLacZ, GPCPDGF and XFMPDGF cells, we
measured the number of motile cells towards serially diluted CM gathered from the U-87,
U-251 and XFMPDGF tumor-derived cells. Here, we report the effective fold increase in
migratory cells and the statistical significance. As shown in Fig. 3, GPCLacZ cells exhibited
a dosage-dependent migratory response towards U-87, U-251, and XFMPDGF CM. The
highest number of motile cells was measured in response to non-diluted conditioned media,
100% or CM100, and was reduced when exposed to 50% diluted media, CM50, and 25%
diluted conditioned media, CM25, from identical tumor sources. The GPCLacZ cells
exhibited a maximum RCF of 10 when migrating towards U-87 CM100 as compared to
control experiments. Chemotaxis of GPCLacZ cells in response to XFMPDGF CM100
exhibited a maximum RCF of 3.9. GPCPDGF cells in response to CM of U-87, U-251, and
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XFMPDGF exhibited RCF values of 8, 5, and 6, respectively. Similarly, XFMPDGF cells in
response to CM of U-87 and XFMPDGF exhibited RCF values of 4 (Figs. 3a, 3c). Lastly,
RCF values for all cells towards CM100 were reduced to 1 (i.e. level of controls) when
neutralizing antibodies were used to block effects of HGF and TGF-α (data not shown).
Glial Progenitor Cells Exhibit Different Expression Levels of Cognate Receptors
We next examined GPC expression of 3 cognate receptors of key cytokines known to be
highly chemoattractive to cells derived from glial tumors and present within tumor
CM4,10,27,30,70,81,83: cMet, the receptor for HGF, Epidermal Growth Factor Receptor
(EGFR), the receptor for the Epidermal Growth Factor (EGF) and TGF-α ligands, and
Platelet-Derived Growth Factor Receptor beta (PDGFRβ). Western blot analysis shown in
Fig. 4 illustrates that all GPC types express different levels of the 3 receptors, each
benchmarked against the well-studied U-87 cell line in each experiment.11 As seen,
GPCLacZ, GPCkRas, and GPCPDGF express cMet to approximately the same level as U-87
cells. GPCPDGF and GPCkRas express PDGFR at levels similar to U-87, while GPCLacZ
expression of PDGFR was minimal. Lastly, GPCPDGF and GPCLacZ expressed EGFR at
levels less than U-87 and GPCkRas illustrated trace amounts of EGFR.
Glial Progenitor Cells Exhibit Increased Chemotaxis in Response to Ultra Low
Concentrations of Exogenous HGF, PDGF, and TGF-α
With the varying levels of GPC growth factor receptors established, the next experiments
utilized transwell assays to examine the migratory responses of GPCLacZ, GPCPDGF,
GPCkRas, and U-87 cells towards different concentrations of HGF, PDGF, and TGF-α. As
shown in Fig. 5, GPCLacZ demonstrated the highest RCF value of 58 in response to a 10 pM
HGF solution, an RCF of 12.7 in response to 1 pM PDGF and an RCF of 8.75 in response to
1 pM of TGF-α. By contrast, a concentration of 1 pM HGF induced motile GPCPDGF cells
with a RCF value of 8, while 100 pM TGF-α induced a 9-fold migration response in
GPCPDGF cells over controls. The migration of GPCkRas cells was highest when exposed to
a solution of 1 pM TGF-α, exhibiting an RCF value of 38, an RCF value of 10 toward 1 pM
HGF, and an RCF value of 4 toward 1 pM HGF. Lastly, U-87 cells exhibited their largest
RCF value of 6.64 towards 1 nM HGF.
Glial Progenitor Cell Receptor Expression is Up- or Down-Regulated when Stimulated with
Exogenous Growth Factor
While the HGF and PDGF ligands demonstrated chemotactic abilities, all subsequent
experiments focused particularly on the chemotaxis induced by exogenous TGF-α because it
was shown to be a chemoattractant for all of the cell types studied here; its receptor, EGFR,
is an extensively-studied oncogene present in diverse tumors of varying grade43,46; and
because it has been shown to be involved in tumor cell migration.18,55,86 In the next
experiments, western blot analysis was used to detect changes in phosphorylated EGFR
(pEGFR) expression between cells that were stimulated and non-stimulated with TGF-α.
Detection of pEGFR was positive in non-treated (control) populations of GPCLacZ,
GPCPDGF and GPCkRas cells, as shown in Fig. 6. The intensity of each band was normalized
to a value of I = 1 using device software as described previously. Upon stimulation with
TGF-α, elevated levels of pEGFR were detected in the GPCLacZ and GPCPDGF cell types
with average intensity values of I = 2.63 and I = 5.05, respectively. Conversely, the average
intensity of pEGFR upon TGF-α stimulation in the GPCkRas cell population was lower than
control, at I = 0.49.
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The μLane System Facilitates Analysis of Cell Migration within Controlled
Microenvironments
Given the varying levels of EGFR expression and differences in its regulation in response to
TGF-α stimulation, we next examined how specific microenvironments of TGF-α affected
the chemotaxis of the genetically-altered GPC populations studied. We examined the
migration of the GPCLacZ, GPCPDGF, GPCkRas, and U-87 cell populations within our
laboratory-developed microfluidic system, the μLane, in order to identify the different
migratory phenotypes and distances traveled in response to known TGF-α concentration
profiles. First, no cells were present at the start of microchannel experiments, facilitating
visualization of cells migrating outwards from the sink reservoir and into the microchannel
over time. Second, control experiments using U-87 cells incubated within a 3D matrix
without exogenous growth factors verified that the μLane system maintained cell viability
for up to 7 days (data not shown). In addition, as cells were seen to begin proliferating
within the μLane after 40 h, cell migration experiments were limited to a 36-h period in
order to exclude effects of cell division in our analysis. Last, cell distances traveled in the
μLane system were measured in 200 μm increments. We determined this number to be
significant because it was the average thickness of matrix-coated filters used during
transwell assays, i.e. the maximum migration distance in those initial experiments.
Figure 7 illustrates the migration of GPCLacZ, GPCPDGF, GPCkRas, and U-87 cells within
μLane microenvironments generated by using 0 pM, 10 pM and 100 pM TGF-α within 3D
matrix. No GPCLacZ or GPCPDGF cells were seen to migrate into the channel within 36 h
when no additional exogenous growth factors were added within the matrix (i.e. control
experiments). In contrast, the GPCkRas and U-87 cells were seen to migrate within the
channel in low numbers during control experiments (Figs. 7A1–7A4). When cells were
exposed to gradients generated by an initial TGF-α concentration of 10 pM, all cell
populations displayed enhanced migration into the channels (Figs. 7B1–7B4). In addition,
each cell type exhibited a distinct migratory phenotype. GPCLacZ cells migrated as single
cells, GPCPDGF cells exhibited group migration, while GPCkRas and U-87 MG cells
migrated in close association to each other resembling chains of migrating cells. Lastly,
experiments recorded that GPCLacZ, GPCkRas, and GPCPDGF appeared chemo-repulsed from
the channel entrance when exposed to a microenvironment generated using 100 pM TGF-α,
while the U-87 cells remained migratory (Figs. 7C1–7C4).
The concentrations and concentration gradients experienced by cells within the μLane were
then determined via mathematical modeling, as shown Table 1. As seen, the TGF-α
concentration within the first 600 μm of the μLane was between 0 pM and 0.67 pM (4.02
pg/mL of TGF-α) when 10 pM (60 pg/mL of TGF-α concentration) was used, and an order
of magnitude higher, between 0 pMand 6.7 pM (40.2 pg/mL of TGF-α), when 100 pM TGF-
α was used (600 pg/mL) for chemotaxis experiments. Similarly, the concentration gradient
within these same regions of the channel was approximately 6.8 pg/mL per mm of channel
when 10 pM was used, and 68 pg/mL per mm of channel when 100 pM was used. We note
that because the distribution of concentrations along the channel length does not reach
steady-state in the system until t = 103 h, cells were exposed to highly nonlinear and
transient concentration profiles during all experiments.
Finally, the average number of cells that migrated between three regions within the channel,
i.e. 0–200 μm, 200–400 μm, and 400–600 μm, was measured in response to
microenvironments generated using 10 pM TGF-α as shown in Fig. 8. As seen, between 70–
80% of total migratory GPC cells exhibited maximum migration between 0–200 μm in the
presence of the lowest concentration of less than 0.22 pM (1.32 pg/mL of TGF-α), located at
the interface between the channel entrance and the sink reservoir. GPCLacZ, GPCPDGF, and
GPCkRas cells demonstrated that the remaining 20–30% of total migratory cells were able to
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migrate between 200–400 μm in the presence of a concentrations between 0.22 pM and 0.45
pM (2.7 pg/mL of TGF-α). The majority of U-87 cells, 70%, were also seen to migrate
within the first 200 μm of the microchannel, while 19% of these cells were observed to
migrate between 200 μm and 400 μm into the channel. U-87 was the only cell type able to
migrate distances greater than 400 μm in the channel, with total of 11% of motile cells
observed at this distance.
DISCUSSION
The current study utilized in vitro systems to examine the chemotactic migration of
genetically engineered GPCs toward cytokines known to be secreted by glial tumors for
enhanced tumor growth and dispersal in vivo.10,48,54
Initial experiments first verified that GPCs of different genetic backgrounds were
chemoattracted to conditioned media (CM) obtained from cultures of different tumors, as
well as to different growth factors present within those CM. Our results were in agreement
with the wealth of data demonstrating tumor ability to recruit a diversity of cells by varying
the type and concentration of factors secreted.25,28,37,77,82 However, it was surprising to
observe that all GPC types migrated preferentially towards ultra-dilute solutions (e.g.
picomolar (pM) concentrations) of growth factors when the majority of studies utilize much
higher concentrations to induce the chemotaxis of glioma-derived cells.7,28,47,56,57,61,75 To
examine this further, we studied the migratory responses of each genetically-altered GPC
population in response to different concentrations and gradients of TGF-α.
Our study focused primarily on this EGFR binding ligand because of the well-documented
role of EGFR signaling in glioma43,44,60,84 and the lack of genetic EGFR alteration in any of
the GPCs studied. Interestingly, while the upregulation of pEGFR observed reinforced the
well-established positive signal transduction required for enhanced migration,24,78 treatment
of GPCkRas cells with TGF-α was also seen to result in pEGFR downregulation (Fig. 6).
This was unanticipated because it suggests a negative-feedback suppression mechanism that
was not observed in the cell migratory response (Fig. 5). We suggest that although the cells
respond to specific growth factor concentrations in a manner that significantly enhances
their migration, there exists a threshold upon where the signaling affects that drive the
induced response decrease. While negative feedback is seen in a plethora of systems in
biochemistry, our study is the first to document such phenomena using glial-derived cells. A
detailed investigation of these signaling dynamics is currently under review in our
laboratory. For the continuation of the current work, we then utilized a controlled
microfluidics environment to quantitatively examine the migratory response of GPCs to
known concentration profiles of TGF-α.
TGF-α microenvironments generated via our μLane system revealed significant findings
about the migratory behavior of the GPCs examined. First, despite differences in their
genetic backgrounds, all GPC populations were observed to migrate readily into the
microchannel when exposed to low TGF-α concentrations, but then become largely
chemorepulsed by higher concentrations of the same ligand. The microchannel images
illustrate classic examples of negative feedback in migration, whereby excess ligands
present when receptors have become saturated and bound eliminate or reverse the
biochemical effect.2,80 This migratory behavior is consistent with the picomolar
chemoattraction measured in our initial transwell assay experiments, and is previously
unreported with GPCs or glioma. While in vivo concentration gradients within brain remain
largely unknown, as a result of its highly complex cellular and extracellular matrix structure,
we suggest that ultra-low concentration gradients can be expected to be experienced by cells
in different anatomical regions of brain during injury and disease. A more detailed,
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quantitative estimate of concentration gradients possible in the central nervous system is
currently under investigation by our group, as well as several others.3,6
Our corroborating data implies that the stimuli which produce migratory behavior in glial
tumors may differ from those that attract GPC populations towards the bulk tumor mass.
Differences in the effects of such external cues remain unexamined, and carry significant
consequences for how constituent and/or recruited GPC populations respond to glioma
therapies.13,85
Second, mathematical analysis of the concentration profiles generated within the μLane
illustrated that GPCs were most chemoattracted by environments of both ultra low
concentration and high concentration gradient. While gradients are well-accepted as
chemotactic driving forces42,73 published studies illustrate that chemotaxis is very cell type
specific: Some cell types migrate more readily at higher concentration and gradient,39,74
while others migrate best in shallow gradients with higher concentration.34 Moreover, all
GPCs in our study were observed to migrate much shorter distances in the microchannel
than their tumor cell counterparts. These results seem divert from the characteristic patterns
of GPCs capable of migrating long distances in the brain.20,35 Rather, because GPCs
become stimulated by high concentration gradients at low concentration, our data implies
that GPCs may become most chemoattracted during initial gliomagenesis, where small
numbers of cells express low concentrations of cytokine, rather than by larger tumors
seeking to increase their heterogeneity and potential nourishment.
Last, experiments using μLane systems illustrated distinct patterns of GPC migration that
were surprisingly similar to what has been reported for different types of glial tumor cells in
vivo. Cells of oligodendrogliomas and astrocytomas have been seen to typically invade
normal brain parenchyma by migrating through the white matter tracts as individuals,16,54
similar to the single cell migration exhibited by GPCLacZ cells in our study. By contrast,
gliomas with sarcoma characteristics have been reported to invade the brain primarily by
tracking along blood vessels36,63 such that each cell is in close contact with its motile
neighbors, i.e. exhibiting the chain cell migration observed by GPCkRas cells in our study.
These similarities suggest that perhaps tumors of different types and grade recruit and/or
transform neighboring GPCs into cells with preferred genetic backgrounds, which then
regulate cell migration mechanisms that best enhance tumor dispersal and/or growth. Such
novel research direction is provocative and exciting, as GPCs have remained relatively
unexplored as therapeutic agents in the treatment of glioma.
CONCLUSION
The current study is among the first to examine the in vitro migratory responses of GPC
populations with different genetic backgrounds present in the human disease. Our novel
findings of uniform GPC chemoattraction at ultra-dilute ligand concentrations coupled with
short migration distances underscore the need for a more comprehensive examination of
glioma dispersal and growth mechanisms that incorporates tumor interactions with localized
GPC populations. In addition, analysis of differences in the migratory responses of these
genetically-altered cells advocate study of GPCs as potential therapeutic targets for glioma
treatment.
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RCAS-tv-a System used to produce GPCLacZ, GPCPDGF, GPCPDGF, and XFMPDGF cells.
Ntv-a transgenic mice were created by pronuclear injection with a viral construct that
contained a nestin promoter region. This infection enabled the transcription of the avian
glycoprotein receptor, tv-a, in Nestin-expressing murine glial progenitor cells. Cells that
expressed tv-a were then infected with various RCAS retroviruses in culture to generate
GPCLacZ, GPCPDGF, and GPCkRas cells. XFMPDGF tumors were generated within mice of
INK4a-Arf−/− background that were injected with the RCAS-PDGF-B viral vector.
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Description of the μLane system. (a) A schematic of the μLane system comprised of a sink
and source reservoir connected by a microchannel of 100 μm by 100 μm cross-section. (b)
Image of a μLane system fabricated in our laboratory using glass-PDMS. (c) Mathematical
simulation of the distribution of ligand concentration within the microchannel over time, t.
(d) Inset highlights the concentration profile present within the first 1000 μm of the channel
closest to the sink reservoir at the experimental time of t = 36 h.
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Dose-dependent response of GPCLacZ, GPCPDGF and GPCkRas glial progenitor cells and
U-87 tumor cells to glioma conditioned media (CM). Bar graphs depict values of Relative
Chemoattractant Factor (RCF), defined as the number of motile cells towards experimental
conditions normalized by the number of motile cells towards control conditions (in this case
non-supplemented DMEM). The normalized number of motile cells measured in response to
non-diluted conditioned media, CM100, 50% conditioned media, CM50, and 25%
conditioned media, CM25, of (a) U-87, (b) U-251, and (c) XFMPDGF. All experiments
utilized non-supplemented DMEM as controls (i.e. RCF = 1). p ≤0.05 *means significances.
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GPCPDGF, GPCkRas, GPCLacZ, and U-87 cell expression of total Platelet Derived Growth
Factor Receptor (PDGFR), Epidermal Growth Factor Receptor (EGFR), and cMET
(receptor for Hepatocyte Growth Factor, HGF) examined via Western blot analysis. β-actin
was used as a loading control.
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Dose-dependent response of GPCLacZ, GPCPDGF, GPCkRas glial progenitor cells and U-87
tumor cells to a concentration range of the (a) Hepatocyte Growth Factor (HGF), (b)
Platelet-derived Growth Factor BB (PDGF) and (c) Transforming Growth Factor-α (TGF-
α). Bar graphs depict values of Relative Chemoattractant Factor (RCF), defined as the
number of motile cells towards experimental conditions normalized by the number of motile
cells towards exogenous growth factors.
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Expression of phosphorylated Epidermal Growth Factor Receptor (pEGFR) in GPCLacZ,
GPCPDGF, and GPCkRas glial progenitor cells stimulated and unstimulated with TGF-α
ligand as examined via Western blot analysis. The average intensity of bands, I, was divided
by the intensity of bands at control conditions using device software in order to report values
that reflect a fold-increase of fold-decrease of pEGFR intensity per experiment. β-actin was
used as a loading control.
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Migration of GPCLacZ, GPCPDGF, GPCkRas, and U-87 cells within the μLane system after
36 h in response to concentration gradients generated by using initial concentrations of (A1–
A4) 0 pM (control), (B1–B4) 10 pM and (C1–C4) 100 pM of TGF-α in the sink reservoir.
The left hand side of images A1–A4 and B1–B4 represent the interface between the sink
reservoir and the microchannel. The nuclei of representative cells are indicated by blue
ovals. Scale bars = 200 μm.
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Average numbers of migratory cells and the average maximum distances traveled within the
μLane. Data was calculated using microenvironments generated 36 h after using 10 pM
TGF-α in the source reservoir. The percentage of each cell type observed to migrate
distances between 0–200 μm, 200–400 μm and 400–600 μm are shown.
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